<DOC>
	<DOCNO>NCT00120289</DOCNO>
	<brief_summary>The purpose study determine whether raise `` good cholesterol '' drug base vitamin niacin , lower `` bad cholesterol '' statin drug , prevent heart disease statin alone .</brief_summary>
	<brief_title>Niacin Plus Statin Prevent Vascular Events</brief_title>
	<detailed_description>BACKGROUND : Coronary heart disease ( CHD ) remain leading cause death disability Western world , approximately 12.6 million individual United States history myocardial infarction ( MI ) , angina , . There mount evidence `` conventional '' therapy aim traditional risk factor optimize clinical outcome . For example , Heart Protection Study 20,536 subject , 5-year risk first major vascular event ( nonfatal MI CHD death , stroke , coronary noncoronary revascularization ) among placebo-treated patient 25 % . Treatment simvastatin reduce risk 20 % 5 year , would project 10-year risk 40 % . ( The National Cholesterol Education Program Adult Treatment Panel III consider `` high risk '' CHD equivalent 10-year risk event great 20 % . ) Even among patient enter study baseline low density lipoprotein cholesterol ( LDL-C ) already near goal ( i.e. , LDL-C le 116 mg/dL ) achieve mean on-trial LDL-C 70 mg/dL simvastatin , 5-year risk event still 18 % ( project 10-year risk 36 % ) . This residual unacceptably high risk likely due increase prevalence obesity , type II diabetes mellitus , metabolic syndrome . These disorder typically accompany constellation abnormality include impaired glycemic control , hypertension , procoagulant inflammatory state , atherogenic dyslipidemia . The latter include wide spectrum lipid abnormality ( low HDL-C , high triglyceride triglyceride-rich remnant lipoprotein , preponderance small dense , highly-oxidizable LDL particle ) . Conventional LDL-C-focused therapy effective target type dyslipidemia . Evidence therapy direct atherogenic dyslipidemia among patient CHD low outcome show gemfibrozil VA-HIT trial , show 22 24 % cardiovascular ( CV ) event reduction raise HDL-C ( average 6 % ) lower triglyceride ( average 31 % ) . Niacin even effective agent simultaneously raise HDL-C lower triglyceride level small dense LDL , hold promise among exist therapy substantial risk reduction population add statin . This demonstrate HDL Atherosclerosis Treatment Study ( HATS ) trial atherosclerosis progression virtually halt CV event reduce 60 90 % use combine niacin plus statin therapy . DESIGN NARRATIVE : AIM-HIGH multicenter , randomize , double-blind , parallel-group , control clinical trial design test whether drug combination extend release niacin plus simvastatin superior simvastatin alone , comparable level on-treatment LDL-C , delay time first major CV disease outcome 4-year median follow-up patient atherogenic dyslipidemia . Prior clinical trial find 25 35 % CV risk reduction use statin monotherapy ( i.e. , event rate 2/3 3/4 placebo rate ) . The study need confirm whether statin-niacin combination therapy , design target wider spectrum dyslipidemic factor addition LDL-C , provide substantial ( great 50 % ) reduction CV event . Epidemiologic study confirm high prevalence atherogenic dyslipidemia impact CV event rate . Preliminary clinical trial suggest target factor dyslipidemic therapy reduce CV event . The study enroll estimate 3,300 men woman 45 year old high risk recurrent CV event virtue establish CV disease together two dyslipidemic element metabolic syndrome : low HDL-cholesterol ( HDL-C ) ( less equal 40 mg/dl ) high triglyceride ( TG ) ( great equal 150 mg/dl ) . The study specifically aim test hypothesis primary composite clinical end point CHD death , nonfatal MI , ischemic stroke , hospitalization acute coronary syndrome objective evidence ischemia ( troponin-positive ST-segment deviation ) , symptom-driven coronary cerebral revascularization . Secondary end point include composite CHD death , nonfatal MI , ischemic stroke , hospitalization high-risk acute coronary syndrome ; composite CHD death , nonfatal MI ischemic stroke ; cardiovascular mortality .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Men woman age 45 old establish vascular disease atherogenic dyslipidemia Established vascular disease define one following : ( 1 ) document coronary artery disease ( CAD ) ; ( 2 ) document cerebrovascular carotid disease ; ( 3 ) document symptomatic peripheral arterial disease ( PAD ) Atherogenic dyslipidemia define : ( 1 ) LDLC le equal 160 mg/dL ( 4.1 mmol/L ) ; ( 2 ) HDLC le equal 40 mg/dL ( 1.0 mmol/L ) men less equal 50 mg/dL ( 1.3 mmol/L ) woman ; ( 3 ) TG great equal 150 mg/dL ( 1.7 mmol/L ) less equal 400 mg/dL ( 4.5 mmol/L ) For patient enter trial statin : ( 1 ) upper limit LDLC adjust accord specific statin statin dose ; ( 2 ) HDLC le equal 42 mg/dL ( 1.1 mmol/L ) men less equal 53 mg/dL ( 1.4 mmol/L ) woman ; ( 3 ) TG great equal 125 mg/dL ( 1.4 mmol/L ) less equal 400 mg/DL ( 4.5 mmol/L ) Coronary artery bypass graft ( CABG ) surgery within 1 year plan enrollment ( runin phase ) Percutaneous coronary intervention ( PCI ) within 4 week plan enrollment ( runin phase ) Hospitalization acute coronary syndrome discharge within 4 week plan enrollment ( runin phase ) Fasting glucose great 180 mg/dL ( 10 mmol/L ) hemoglobin A1C great 9 % For patient diabetes , inability refusal use glucometer home monitoring blood glucose Concomitant use drug high probability increase risk hepatotoxicity myopathy , predominantly metabolize cytochrome P450 system 3A4 , include limited cyclosporine , gemfibrozil , fenofibrate , itraconazole , ketoconazole , HIV protease inhibitor , nefazodone , verapamil , amiodarone ; lipidlowering drug ( investigational drug ) statin , bileacid sequestrants , cholesterol absorption inhibitor ( e.g. , ezetimibe ) , fibrates highdose , antioxidant vitamin ( vitamin C , E , beta carotene ) interfere HDLraising effect niacin</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>